Protein C News and Research

RSS

Cardium Therapeutics reports positive findings from Excellarate Phase 1/2 clinical study

Cardium Therapeutics today announced the publication of positive findings from the open label multi-center Phase 1/2 clinical study of Excellarate(TM) (GAM501, Ad5PDGF-B / 2.6% collagen), its product candidate for the potential treatment of non-healing diabetic foot ulcers.

19 Oct 2009

Biogen Idec and Biovitrum to conduct rFIXFc clinical trial in hemophilia B patients

Biogen Idec and Biovitrum AB (STO: BVT) today announced that they plan to advance the companies’ long-acting, fully-recombinant Factor IX Fc fusion protein (rFIXFc) into a registrational clinical trial in hemophilia B patients.

19 Oct 2009

Research study provides supportive evidence for using ATR inhibitors in cancer therapy

A study published in the October issue of Nature Genetics demonstrates that loss of the tumor-suppressor protein p53, coupled with elimination of the DNA-maintenance protein ATR, severely disrupts tissue maintenance in mice.

19 Oct 2009

Bedside coaching and exercising for ICU patients on ventilators

Few people have thought about providing an exercise workout in the intensive care unit, especially for patients on ventilators - even those who are comatose - but a researcher from Frances Payne Bolton School of Nursing at Case Western Reserve University will be doing some bedside coaching and exercising to get patients stretching and flexing their muscles.

19 Oct 2009

Fate Therapeutics announces human iPSC generation using a combination of small molecules

Fate Therapeutics, Inc. announced today the generation of human induced-pluripotent stem cells (iPSCs) using a combination of small molecules that significantly improves the speed and efficiency of reprogramming.

19 Oct 2009

Findings may yield new treatments for COPD

A genetic mutation found in four children born with multiple abnormalities may provide insight into potential treatments for newborn lung distress and chronic obstructive pulmonary disease (COPD).

19 Oct 2009

Multi-million dollar cooperative agreement for SMA drug development program

Paratek Pharmaceuticals (Boston, MA) and Families of Spinal Muscular Atrophy (Elk Grove Village, IL) announced today that a jointly funded drug development program for Spinal Muscular Atrophy (SMA) has been awarded a multi-million dollar cooperative agreement from the National Institute of Neurological Disorders and Stroke (NINDS).

19 Oct 2009

APP balance critical for normal neuronal development

New data about amyloid precursor protein, or APP, a protein implicated in development of Alzheimer's disease, suggests it also may have a positive role -- directly affecting learning and memory during brain development. So is APP good or bad? Researchers at Georgetown University Medical Center say both, and that a balance of APP is critical.

19 Oct 2009

Enzo Biochem to release a new catalog dealing with epigenetics and chromatin modification

Enzo Biochem, Inc. today said that its Life Sciences subsidiary will release a new catalog dealing with “Epigenetics & Chromatin Modification” at the Society for Neuroscience’s, Neuroscience 2009 conference, beginning October 17, 2009, in Chicago, Illinois.

15 Oct 2009

New range of foods from marine animals and plants to help fight human diseases

Milk drinks that lower blood pressure, meat products that reduce the risk of heart disease, chocolate that calms you down and a new range of foods that can fight obesity can be created from marine animals and plants. Japan already has several product ranges on the shelves and research programmes are underway all over the world to create more.

15 Oct 2009

New maintenance medium for human embryonic and pluripotent stem cells

STEMCELL Technologies Inc. (STEMCELL) is pleased to announce the release of TeSR™2, a defined, animal-protein free maintenance medium for human embryonic and induced pluripotent stem cells. This medium takes a step towards addressing the needs of researchers working towards the culture of their cells in a medium free of animal-derived proteins.

15 Oct 2009

MSU receives $6.2 million Morris K. Udall Center of Excellence for Parkinson's disease grant

A team of researchers from Michigan State University and the University of Cincinnati have been awarded a $6.2 million Morris K. Udall Center of Excellence for Parkinson's disease grant.

15 Oct 2009

UT Southwestern Medical Center awarded $15.7M NIH contract to develop a new virus database

The National Institutes of Health has awarded a $15.7 million contract to UT Southwestern Medical Center and Northrop Grumman Corp. to develop an open-access national online database and analysis resource center that will help scientists study and combat viruses such as those that cause hepatitis, encephalitis, smallpox, acute respiratory distress and dengue fever, as well as newly emerging pathogenic viruses.

15 Oct 2009

Curemark commences enrollment in Phase III CM-AT clinical trials for autism treatment

Curemark, LLC, a drug research and development company focused on the treatment of neurological diseases, announced that it has enrolled the first patients in Phase III clinical trials for its autism treatment, CM-AT. The first clinical trial patients have been enrolled at Lake Mary Pediatrics in Orange City, Florida, one of 12 clinical trial sites with a total 170 children across the country.

15 Oct 2009

Genetic diversity thwarts the usefulness of malaria vaccine

Researchers at the University of Maryland School of Medicine Center for Vaccine Development (CVD) have charted the extreme genetic differences that occur over time in the most dangerous malaria parasite in the world. While there is no approved vaccine for malaria, various experimental vaccines are in development.

15 Oct 2009

FDA approves ZyStor Therapeutics' ZC-701 for Phase I human safety trial

ZyStor Therapeutics, Inc., a biotechnology company developing a new class of targeted protein therapeutics for the treatment of Lysosomal Storage Diseases using the Company's proprietary Glycosylation Independent Lysosomal Targeting technology, today announced that it has received clearance from the U. S. Food and Drug Administration to proceed into a clinical trial for its first drug candidate, ZC-701, an enzyme replacement therapy for the treatment of Pompe disease.

14 Oct 2009

Medtronic announces results of study comparing INFUSE Bone Graft to autogenous bone graft

Medtronic, Inc. today announced results of a study comparing the safety and effectiveness of INFUSE® Bone Graft to autogenous bone graft (bone harvested from the patient) when used in maxillary sinus floor augmentation.

14 Oct 2009

Global Bioenergies discovers synthetic metabolic pathway for producing isobutene

Global Bioenergies, located on the Genopole campus close to Paris, has today announced the proof-of-concept of a synthetic metabolic pathway for producing isobutene, a key building block that can be converted into transportation fuels, polymers and various commodity chemicals.

14 Oct 2009

European Patent Office to grant two intellectual property patents to Athera Biotechnologies

Athera Biotechnologies AB, an atherosclerosis R&D company developing novel products for treatment and prevention of cardiovascular disease (CVD), announced today that the European Patent Office intends to grant two key patents related to the Company's intellectual property on its two pharmaceutical candidates Annexin A5 and PC-mAb.

14 Oct 2009

Presentation on L-DOS47 drug formulation and development at Pharmaceutical Industry Conference

Helix BioPharma Corp. (TSX, FSE: "HBP" / OTCQX: HXBPF) today announced that a presentation on L-DOS47 formulation and analytical method development will be made at the "Formulation Strategies for Protein Therapeutics" conference to be held on October 13 to 15, 2009, in Raleigh, North Carolina. The conference is sponsored by IBC Life Sciences.

14 Oct 2009

Protein C News and Research

Cardium Therapeutics reports positive findings from Excellarate Phase 1/2 clinical study

Biogen Idec and Biovitrum to conduct rFIXFc clinical trial in hemophilia B patients

Research study provides supportive evidence for using ATR inhibitors in cancer therapy

Bedside coaching and exercising for ICU patients on ventilators

Fate Therapeutics announces human iPSC generation using a combination of small molecules

Findings may yield new treatments for COPD

Multi-million dollar cooperative agreement for SMA drug development program

APP balance critical for normal neuronal development

Enzo Biochem to release a new catalog dealing with epigenetics and chromatin modification

New range of foods from marine animals and plants to help fight human diseases

New maintenance medium for human embryonic and pluripotent stem cells

MSU receives $6.2 million Morris K. Udall Center of Excellence for Parkinson's disease grant

UT Southwestern Medical Center awarded $15.7M NIH contract to develop a new virus database

Curemark commences enrollment in Phase III CM-AT clinical trials for autism treatment

Genetic diversity thwarts the usefulness of malaria vaccine

FDA approves ZyStor Therapeutics' ZC-701 for Phase I human safety trial

Medtronic announces results of study comparing INFUSE Bone Graft to autogenous bone graft

Global Bioenergies discovers synthetic metabolic pathway for producing isobutene

European Patent Office to grant two intellectual property patents to Athera Biotechnologies

Presentation on L-DOS47 drug formulation and development at Pharmaceutical Industry Conference

Industry Focus eBook - Forensics & toxicology (2nd edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News